Küçük hücreli akciğer kanserlerinde tedavi sonuçları ve prognostik faktörlerin incelenmesi
Loading...
Date
1998
Authors
Özkan, Lütfi
Özgen, Zerrin
Kızılkaya, Orhan
İncekara, Oktay
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
1989-1991. yıllarılan arasında Şişli Etfal Hastanesi Rardyasyon Onkolojisi Kliniğine "Küçük Hücreli Akciğer Kanseri " tanısı ile başvuran ve tedavi edilen 60 olgu prognostik faktörlerin ortaya konabilmesi amacıyla retrospektif olarak incelendi. Ortalama yaş 58 idi (sınırlar 35-85). Olgularda hastalık tanısı balgam sitolojisi. bronkoskopi yada aspirasyon biyopsisi ile konulmuştu. Olguların 15 'i (% 25) sınırlı hastalık. -45 'i (% 75) uygun hastalık olarak değerlendirildi. Olguların büyük bölümünde "Eastern Cooperative Oncology Group (ECOG " performance duruma' 2 ve 3 olarak bulunan . Sınırlı hastalık saptanan 15 olgunun sekizine (% 53) kemoradyoterapi ve yedisine de (% 47) yalnızca kemoterapi uygulanırken yaygın hastalık saptanan olguların 16 sına (% 36) kemo radyoterapi ve 29 'unada % 64) yalnızca kemoterapi uygulanmıştır. Sistemik kemoterapi amacıylla en sık kullanılan ajanlar yalnlızca kemoterapi idi. Toplam kemoterapi kür sayısı 6 iken arası interval 28 gün olarak belirlendi. Radyoterapı sınırlı hastalık olan olgularda 3 kür kemoterapi sonrasında 30Gy (10*03 Gy olarak verildi. Başlangıç vena kava süperior sendromu olan olgularda radyoterapi kemoterapi öncesi uygulandı.Tüm olgular içinde medyan sağkalım 10.7 ay olarak bulundu. Medyum sağkalım süresi sınırlı hastalıkta 17 ay iken yaygın hastalıkta 8,6 ay idi. Kemoradyoterapi uygulananlarda medyum sağkalım 13,3 ay iken yalnızca kemoterapi uygulamalarda bu süre 8,7 ay olarak hesaplandı. Hastaların ECOG performans skoru da diğer önemli prognostik faktör olarak ortaya çıktı.
Sixty patients with small lung cancer, who were admitted to Şişli Children's Hospital between 1989 and 1991. were analyzed trosıtivel' to define prognostic factors. Median age was 58 with the range ( 35-85. Fijieen points (15 %) were assessed as limited disease (LD) and -15 (75 %) as disseminated disease (DDJ. ECOG Performance Status (PS) were found to be 2 and 3 in the majority of The cases. Eight 15 patients with LD f 53 %) received chemoradiotherapy (CRT) and 7 received chemotherapy alone (CT. -47%) while 16 parties with DD ( 36 %1 had CRT and had CT r6-l % ). Most used CT agenls were cisplatin and etoposide. Median number of CT eyeles ras 6 and int alı 8RT was administered with Co60 machine after 3 eyeles of CT:Total RT dose was 3U Gy h 3 Gy per fraction giı en fn 12 d(l)·s. RT was given before CTjor patients with vena cava .wperior syndrome. Median (MS) was 10.7 months for the whole group. Extent of disease. ECOG PS and treatment modality were the most important prognostic factors. MS 17 months for patients with LD and 8. 6 months for patients with DD fp< 0.000. lt was 16. 8.11.1 and 5.5 months for patients with ECOG 1.2 and 3. respectively (p=0.015 and p< 0.000). MS was significantly heller in patients who received combined modality' treatment (p= 0.01 )
Sixty patients with small lung cancer, who were admitted to Şişli Children's Hospital between 1989 and 1991. were analyzed trosıtivel' to define prognostic factors. Median age was 58 with the range ( 35-85. Fijieen points (15 %) were assessed as limited disease (LD) and -15 (75 %) as disseminated disease (DDJ. ECOG Performance Status (PS) were found to be 2 and 3 in the majority of The cases. Eight 15 patients with LD f 53 %) received chemoradiotherapy (CRT) and 7 received chemotherapy alone (CT. -47%) while 16 parties with DD ( 36 %1 had CRT and had CT r6-l % ). Most used CT agenls were cisplatin and etoposide. Median number of CT eyeles ras 6 and int alı 8RT was administered with Co60 machine after 3 eyeles of CT:Total RT dose was 3U Gy h 3 Gy per fraction giı en fn 12 d(l)·s. RT was given before CTjor patients with vena cava .wperior syndrome. Median (MS) was 10.7 months for the whole group. Extent of disease. ECOG PS and treatment modality were the most important prognostic factors. MS 17 months for patients with LD and 8. 6 months for patients with DD fp< 0.000. lt was 16. 8.11.1 and 5.5 months for patients with ECOG 1.2 and 3. respectively (p=0.015 and p< 0.000). MS was significantly heller in patients who received combined modality' treatment (p= 0.01 )
Description
Keywords
Küçük hücreli akciğer kanseri, Radyoterapi, Kemoterapi, Kemoradyotcrapi, Prognostik, Faktör, Smail cell lung carcinoma, Radiotherapy, Chemotherapy, Chemoradiotherapy, Prognostic factor
Citation
Özkan, L. vd. (1998). ''Küçük hücreli akciğer kanserlerinde tedavi sonuçları ve prognostik faktörlerin incelenmesi''. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 25(1-2-3), 35-39.